dibekacin and Corneal-Ulcer

Topics: Anti-Infective Agents; Cataract Extraction; Cornea; Corneal Ulcer; Dibekacin; DNA, Bacterial; Eye Infections, Bacterial; Female; Humans; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Surgical Wound Infection; Suture Techniques

The effects of habekacin on corneal ulceration, caused by Pseudomonas aeruginosa IFO 3455, were studied in mice, in comparison with gentamicin and tobramycin. The minimal inhibitory concentrations of the antibiotics for the organism were: habekacin 2 microgram/ml, gentamicin 2 microgram/ml, and tobramycin 1 microgram/ml. Habekacin showed protective and therapeutic effects on Pseudomonas keratitis. The 50% effective dose was approximately 1 microgram per mouse, when the drug was topically applied three hours after the infection, and about 0.2 mg per mouse, when the antibiotic was intramuscularly injected one hour after the bacterial challenge to the cornea. Significant therapeutic and protective activities of habekacin were observed even by starting the topical and/or intramuscular treatment after the corneal ulcers were formed: i.e. 15 hours after the bacterial infection. Complete cure of Pseudomonas keratitis was found within a week in a number of the infected mice by both topical and systemic administrations of the drug. The protective and therapeutic effects of habekacin were comparable to those of gentamicin and tobramycin.

Topics: Administration, Topical; Aminoglycosides; Animals; Anti-Bacterial Agents; Corneal Ulcer; Dibekacin; Injections, Intramuscular; Keratitis; Male; Mice; Pseudomonas Infections

The effectiveness of immunizing mice with protease toxoid (PT) or elastase toxoid (ET) on the corneal ulcerization due to either protease or elastase were investigated. Consequently, mice immunized with either PT or ET were protected from corneal ulcers experimentally induced by the homologous enzyme, either protease or elastase. Similarly, two kinds of rabbit immune sera, anti-PT and anti-ET, were found to prevent corneal ulcers by the homologous enzyme. Then, the therapeutic effects of vaccination with a single or mixed vaccine consisting of one, two or three components, i.e., PT, ET and/or the common antigen (OEP) of Pseudomonas aeruginosa, were examined on corneal ulcers in mice produced by live cultures of the bacteria. For the same purpose, administration of a single or combined rabbit immune sera against PT, ET and OEP was conducted. As a result, vaccination with the three-component-mixed vaccine or administration with rabbit immune sera combined with anti-PT and anti-ET sera in addition to anti-OEP serum, were found to be the most effective in preventing corneal ulceration as well as in treating corneal ulcers in mice.

Topics: Animals; Antigens, Bacterial; Bacterial Vaccines; Corneal Ulcer; Dibekacin; Pancreatic Elastase; Peptide Hydrolases; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Toxoids

Synergistic effects of immune gamma-globulin fraction containing antibodies of OPE, protease and elastase of Pseudomonas aeruginosa on the activities of antibiotic, dibekacin (DKB), in the cornea of mice were examined for the purpose of studying therapy for corneal ulcers due to Pseudomonal infection. In the case of the intramuscular injection, a medium effective dose (ED50) of DKB alone against corneal ulcers caused by strain IID 1210 of P. aeruginosa in experimental mice was 620 mug per mouse. When 15.6 to 18.7 mg of gamma-globulin fraction was subcutaneously given to each mouse prior to the infection with strain IID 1210, opacity instead of severe ulcers was observed only in the central area of cornea. The immune gamma-globulin fraction was far more effective in the protection of cornea from the infection than the calf serum that showed no antibody titer against OEP, protease and elastase. The ED50 values of DKB's combined with the immune gamma-globulin, Fr. 1 and Fr. 2, and the calf serum were 34 and 73, and 480 mug per mouse respectively. There was found no statistical difference in ED50 value between DKB combined with the calf serum and one without it. There was, however, significant difference in ED50 value between DKB's combined with Fr. 1 and Fr. 2, and one with the calf serum. When DKB alone is dropped in the eye of mouse for the protection, the ED50 value was 15 mug per mouse. When 1.56 to 1.87 mg of the immune gamma-globulin fraction was dropped in the eye after the infection with P. aeruginosa, there was observed no protection against corneal ulcers. the ED50 values of DKB's combined with Fr. 1, Fr. 2 and the calf serum were 0.96, 0.94 and 13 mug per mouse, respectively. There was no significant difference between the ED50 values of 0.96 and 0.94 mug, and between 15 and 18 mug. There was, however, significant difference between the former ED50 values (0.96 and 0.94 mug) and the latter ones (15 and 18 mug). The combination of DKB and the immune gamma-globulin fraction was found to be superior to the combination of DKB and the calf serum in the therapeutic effect on corneal ulcers caused by strain IID 1210 of P. aeruginosa.

Topics: Abscess; Animals; Antibodies, Bacterial; Antigens, Bacterial; Corneal Opacity; Corneal Ulcer; Dibekacin; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Immune Sera; Immunoglobulin G; Kanamycin; Mice; Pseudomonas aeruginosa; Pseudomonas Infections